Navigating recurrent immune-mediated thrombotic thrombocytopenic purpura (iTTP) in pregnancy: A case report and literature review

IF 1.4 4区医学 Q4 HEMATOLOGY

Transfusion and Apheresis Science Pub Date : 2025-06-27 DOI:10.1016/j.transci.2025.104199

Mohadese Golsorkhi , Niloufar Ebrahimi , Shahram Kordasti , Sayna Norouzi , Amir Abdipour

引用次数: 0

Abstract

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare and potentially fatal thrombotic microangiopathy characterized by thrombocytopenia and microangiopathic hemolytic anemia. It primarily affects women of childbearing age, with pregnancy being a significant precipitating factor. TTP overlaps with other pregnancy-related conditions, such as HELLP syndrome, complicating diagnosis and necessitating urgent clinical evaluation and intervention. Plasma-based therapies have significantly improved the prognosis for these patients. Additionally, serial follow-up of ADAMTS-13 activity is recommended at the preconception stage and throughout pregnancy for women with a history of TTP. In this report, we present a case of a 32-year-old patient with a recurrent iTTP on her 11-week gestation of the second pregnancy, which was successfully managed with therapeutic plasma exchange (TPE) and corticosteroids.

查看原文本刊更多论文

妊娠期复发性免疫介导的血栓性血小板减少性紫癜（iTTP）： 1例报告及文献复习

免疫介导的血栓性血小板减少性紫癜（iTTP）是一种罕见和潜在致命的血栓性微血管疾病，其特征是血小板减少和微血管致病性溶血性贫血。它主要影响育龄妇女，怀孕是一个重要的诱发因素。TTP与其他妊娠相关疾病（如HELLP综合征）重叠，使诊断复杂化，需要紧急临床评估和干预。以血浆为基础的治疗显著改善了这些患者的预后。此外，对于有TTP病史的妇女，建议在孕前阶段和整个妊娠期间对ADAMTS-13活性进行连续随访。在本报告中，我们报告了一位32岁的患者，在她第二次怀孕的11周妊娠时复发性iTTP，并成功地通过治疗性血浆交换（TPE）和皮质类固醇治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion and Apheresis Science 医学-血液学

CiteScore

3.60

自引率

5.30%

发文量

181

审稿时长

42 days

期刊介绍： Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.